Craft

BrightGene

Stock Price

¥30.3

2024-10-29

Market Capitalization

¥12.7 B

2024-10-29

Revenue

¥1.2 B

FY, 2025

BrightGene Summary

Company Summary

Overview
BrightGene (博瑞生物医药) is a research-driven biopharmaceutical company that engages in the R&D and manufacturing of medicines. Its products include immuno-oncological therapeutic agents, antibody-drug conjugates for solid tumor, non-antibody dependent tumor-targeting conjugates for brain cancer and solid tumor brain-metastasis, etc.
Type
Public
Status
Active
Founded
2001
HQ
Suzhou Shi, CN | view all locations
Website
http://www.bright-gene.com
Cybersecurity rating
Sectors

LocationsView all

3 locations detected

  • Suzhou Shi, Jiangsu Sheng HQ

    China

    218 Xinghu St, Wuzhong Qu

  • Taizhou Shi, Jiangsu Sheng

    China

    Bin Jiang Nan Lu, Taixing Shi

  • Chongqing

    China

    Beibei District

BrightGene Financials

Summary Financials

Revenue (FY, 2025)
¥1.2B
Gross profit (FY, 2025)
¥609.0M
Net income (FY, 2025)
¥37.0M
Cash (FY, 2025)
¥955.1M
EBIT (FY, 2025)
¥85.5M
Enterprise value
$14.5B

Footer menu